Michael S Broder1, Tiffany P Quock2, Eunice Chang3, Sheila R Reddy4, Rajni Agarwal-Hashmi5, Sally Arai6, Kathleen F Villa7. 1. President and CEO, Partnership for Health Analytic Research, Beverly Hills, CA. 2. Associate Director, Health Economics & Outcomes Research, Jazz Pharmaceuticals, Palo Alto, CA, during this study. 3. Chief Statistician, Partnership for Health Analytic Research. 4. Director, Health Services Research, Partnership for Health Analytic Research. 5. Associate Professor, Pediatrics (Stem Cell Transplantation), Stanford University School of Medicine, Palo Alto, CA. 6. Associate Professor, Medicine (Blood and Marrow Transplantation), Stanford University School of Medicine. 7. Executive Director, Health Economics & Outcomes Research, Jazz Pharmaceuticals.
Abstract
BACKGROUND: Hematopoietic stem-cell transplantation (HSCT) requires highly specialized, resource-intensive care. Myeloablative conditioning regimens used before HSCT generally require inpatient stays and are more intensive than other preparative regimens, and may therefore be more costly. OBJECTIVE: To estimate the costs associated with inpatient HSCT according to the type of the conditioning regimen used and other potential contributors to the overall cost of the procedure. METHOD: We used data from the Truven Health MarketScan insurance claims database to analyze healthcare costs for pediatric (age <18 years) and adult (age ≥18 years) patients who had autologous or allogeneic inpatient HSCT between January 1, 2010, and September 23, 2013. We developed an algorithm to determine whether conditioning regimens were myeloablative or nonmyeloablative/reduced intensity. RESULTS: We identified a sample of 1562 patients who had inpatient HSCT during the study period for whom the transplant type and the conditioning regimen were determinable: 398 patients had myeloablative allogeneic HSCT; 195 patients had nonmyeloablative/reduced-intensity allogeneic HSCT; and 969 patients had myeloablative autologous HSCT. The median total healthcare cost at 100 days was $289,283 for the myeloablative allogeneic regimen cohort compared with $253,467 for the nonmyeloablative/reduced-intensity allogeneic regimen cohort, and $140,792 for the myeloablative autologous regimen cohort. The mean hospital length of stay for the index (first claim of) HSCT was 35.6 days in the myeloablative allogeneic regimen cohort, 26.6 days in the nonmyeloablative/reduced-intensity allogeneic cohort, and 21.8 days in the myeloablative autologous regimen cohort. CONCLUSION: Allogeneic HSCT was more expensive than autologous HSCT, regardless of the regimen used. Myeloablative conditioning regimens led to higher overall costs than nonmyeloablative/reduced-intensity regimens in the allogeneic HSCT cohort, indicating a greater cost burden associated with inpatient services for higher-intensity preparative conditioning regimens. Pediatric patients had higher costs than adult patients. Future research should involve validating the algorithm for identifying conditioning regimens using clinical data.
BACKGROUND: Hematopoietic stem-cell transplantation (HSCT) requires highly specialized, resource-intensive care. Myeloablative conditioning regimens used before HSCT generally require inpatient stays and are more intensive than other preparative regimens, and may therefore be more costly. OBJECTIVE: To estimate the costs associated with inpatient HSCT according to the type of the conditioning regimen used and other potential contributors to the overall cost of the procedure. METHOD: We used data from the Truven Health MarketScan insurance claims database to analyze healthcare costs for pediatric (age <18 years) and adult (age ≥18 years) patients who had autologous or allogeneic inpatient HSCT between January 1, 2010, and September 23, 2013. We developed an algorithm to determine whether conditioning regimens were myeloablative or nonmyeloablative/reduced intensity. RESULTS: We identified a sample of 1562 patients who had inpatient HSCT during the study period for whom the transplant type and the conditioning regimen were determinable: 398 patients had myeloablative allogeneic HSCT; 195 patients had nonmyeloablative/reduced-intensity allogeneic HSCT; and 969 patients had myeloablative autologous HSCT. The median total healthcare cost at 100 days was $289,283 for the myeloablative allogeneic regimen cohort compared with $253,467 for the nonmyeloablative/reduced-intensity allogeneic regimen cohort, and $140,792 for the myeloablative autologous regimen cohort. The mean hospital length of stay for the index (first claim of) HSCT was 35.6 days in the myeloablative allogeneic regimen cohort, 26.6 days in the nonmyeloablative/reduced-intensity allogeneic cohort, and 21.8 days in the myeloablative autologous regimen cohort. CONCLUSION: Allogeneic HSCT was more expensive than autologous HSCT, regardless of the regimen used. Myeloablative conditioning regimens led to higher overall costs than nonmyeloablative/reduced-intensity regimens in the allogeneic HSCT cohort, indicating a greater cost burden associated with inpatient services for higher-intensity preparative conditioning regimens. Pediatric patients had higher costs than adult patients. Future research should involve validating the algorithm for identifying conditioning regimens using clinical data.
Authors: Fiona L Dignan; Mike N Potter; Mark E Ethell; Matthew Taylor; Lily Lewis; Joy Brennan; Louise McNamara; Steve O Evans; Unell Riley; Faith E Davies; Claire E Dearden; Gareth J Morgan; Bronwen E Shaw Journal: Clin Transplant Date: 2012-12-28 Impact factor: 2.863
Authors: C Cordonnier; S Maury; H Esperou; C Pautas; J Beaune; M Rodet; J-L Lagrange; H Rouard; J-L Beaumont; F Bassompierre; E Glückman; M Kuentz; I Durand-Zaleski Journal: Bone Marrow Transplant Date: 2005-10 Impact factor: 5.483
Authors: Navneet S Majhail; Jaya M Mothukuri; Margaret L Macmillan; Michael R Verneris; Paul J Orchard; John E Wagner; Daniel J Weisdorf Journal: Pediatr Blood Cancer Date: 2010-01 Impact factor: 3.167
Authors: Andrea Bacigalupo; Karen Ballen; Doug Rizzo; Sergio Giralt; Hillard Lazarus; Vincent Ho; Jane Apperley; Shimon Slavin; Marcelo Pasquini; Brenda M Sandmaier; John Barrett; Didier Blaise; Robert Lowski; Mary Horowitz Journal: Biol Blood Marrow Transplant Date: 2009-09-01 Impact factor: 5.742
Authors: A M Saito; D Zahrieh; C Cutler; V T Ho; J H Antin; R J Soiffer; E P Alyea; S J Lee Journal: Bone Marrow Transplant Date: 2007-06-11 Impact factor: 5.483
Authors: Nandita Khera; Barry Storer; Brenda M Sandmaier; Michael K Chapko; Stephanie J Lee Journal: Transplantation Date: 2013-07-15 Impact factor: 4.939
Authors: Michael S Broder; Tiffany P Quock; Eunice Chang; Sheila R Reddy; Rajni Agarwal-Hashmi; Sally Arai; Kathleen F Villa Journal: Am Health Drug Benefits Date: 2017-10
Authors: Jesus Garcia Garcia; Sonya Grillo; Qing Cao; Claudio G Brunstein; Mukta Arora; Margaret L MacMillan; John E Wagner; Daniel J Weisdorf; Shernan G Holtan Journal: Blood Adv Date: 2021-02-09
Authors: Laura F Newell; Kelsea M Shoop; Rebekah J Knight; Sara N Murray; Rogelyn P Kwock; Carol E Jacoby; Susan Slater; Bryon E Allen; Casondra Ottowa; Brad Cota; Peggy L Appel; Rachel J Cook; Richard T Maziarz; Gabrielle Meyers Journal: Cytotherapy Date: 2019-05-10 Impact factor: 5.414
Authors: Erica D Warlick; Celalettin Ustun; Astrid Andreescu; Anthony F Bonagura; Andrew Brunner; Abhinav B Chandra; James M Foran; Mark B Juckett; Tamila L Kindwall-Keller; Virginia M Klimek; Daniel F Pease; David P Steensma; Bryce M Waldman; Mary M Horowitz; Linda J Burns; Nandita Khera Journal: Cancer Date: 2021-08-10 Impact factor: 6.860
Authors: Anastasie M Dunn-Pirio; Benjamin M Heyman; Dan S Kaufman; Revere P Kinkel Journal: Curr Treat Options Neurol Date: 2019-10-17 Impact factor: 3.598
Authors: Michael S Broder; Tiffany P Quock; Eunice Chang; Sheila R Reddy; Rajni Agarwal-Hashmi; Sally Arai; Kathleen F Villa Journal: Am Health Drug Benefits Date: 2017-10
Authors: Gregorio Jaimovich; Robert Peter Gale; Ignacio Hanesman; Alberto Vazquez; Nelson Hammerschlak; Belinda Pinto Simoes; Juan Carlos Fagundo; Marcos Hernandez Jimenez; David Gomez-Almaguer; Ernesto Fanilla; Juan Navarro; Bella Maldonado; Willem Bujan; Julia Palma Behnke; Cristobal Frutos; Amado Karduss; Sebastian Galeano; Juliana Martinez Rolón Journal: Bone Marrow Transplant Date: 2021-05-13 Impact factor: 5.483